Skip to main content
letter
. 2024 Mar 28;109(8):2706–2710. doi: 10.3324/haematol.2024.284962

Table 2.

Clinical characteristics and survival of seven patients with venetoclax/hypomethylating agent-relapsed/refractory acute myeloid leukemia receiving allogeneic stem cell transplant following salvage treatment with cladribine, cytarabine (low-dose), and venetoclax.

graphic file with name 1092706.tab2.jpg